Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma

Peter Murchie; Judith Masthoff; Fiona M. Walter; Kazi Rahman; Julia L. Allan; Nigel Burrows; Charlotte Proby; Amanda J. Lee; Marie Johnston; Amer Durrani; Ivan Depasquale; Billy Brant; Aileen Neilson; Fiona Meredith; Shaun P. Treweek; Susan J. Hall; Alison M. McDonald

doi:10.1186/s13063-019-3453-x

Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma

Peter Murchie^* (Corresponding Author), Judith Masthoff, Fiona M. Walter, Kazi Rahman, Julia L. Allan, Nigel Burrows, Charlotte Proby, Amanda J. Lee, Marie Johnston, Amer Durrani, Ivan Depasquale, Billy Brant, Aileen Neilson, Fiona Meredith, Shaun P. Treweek, Susan J. Hall, Alison M. McDonald

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

18 Downloads (Pure)

Abstract

Background

Melanoma is common; 15,906 people in the UK were diagnosed with melanoma in 2015 and incidence has increased fivefold in 30 years. Melanoma affects old and young people, with poor prognosis once metastatic. UK guidelines recommend people treated for cutaneous melanoma receive extended outpatient, hospital follow up to detect recurrence or new primaries. Such follow up of the growing population of melanoma survivors is burdensome for both individuals and health services. Follow up is important since approximately 20% of patients with early-stage melanoma experience a recurrence and 4–8% develop a new primary; the risk of either is highest in the first 5 years. Achieving Self-directed Integrated Cancer Aftercare (ASICA) is a digital intervention to increase total-skin-self-examination (TSSE) by people treated for melanoma, with usual follow up.

Methods

We aim to recruit 240 adults with a previous first-stage 0-2C primary cutaneous melanoma, from secondary care in North-East Scotland and the East of England. Participants will be randomised to receive the ASICA intervention (a tablet-based digital intervention to prompt and support TSSE) or control group (treatment as usual). Patient-reported and clinical data will be collected at baseline, including the modified Melanoma Worry Scale (MWS), the Hospital Anxiety and Depression Scale (HADs), the EuroQoL 5-dimension 5-level questionnaire (EQ-5D-5 L), and questions about TSSE practice, intentions, self-efficacy and planning. Participants will be followed up by postal questionnaire at 3, 6 and 12 months following randomization, along with a 12-month review of clinical data. The primary timepoint for outcome analyses will be12 months after randomisation.

Discussion

If the ASICA intervention improves the practice of TSSE in those affected by melanoma, this may lead to improved psychological well-being and earlier detection of recurrent and new primary melanoma. This could impact both patients and National Health Service (NHS) resources. This study will determine if a full-scale randomised controlled trial can be undertaken in the UK NHS to provide the high-quality evidence needed to determine the effectiveness of the intervention. ASICA is a pilot study evaluating the effectiveness of the practice of digitally supported TSSE in those affected by melanoma.

Trial registration

Clinical Trials.gov, NCT03328247. Registered on 1 November 2017.

Original language	English
Article number	318
Number of pages	11
Journal	Trials
Volume	20
DOIs	https://doi.org/10.1186/s13063-019-3453-x
Publication status	Published - 3 Jun 2019

Bibliographical note

The authors gratefully acknowledge Joanna Kaniewska, Anne Duncan and Lynda Constable (trial management) for their contributions to the protocol and management of the study.

Funding
The study is supported by a grant from a Cancer Research UK Population Research Committee project award (C10673/A21685). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Cancer Research UK. The funder (through their peer review and funding board review process) approved the study proposal but had no role in the collection, analysis, or interpretation of data, or writing of the report.

Keywords

primary care
melanoma
cancer
randomised controlled trial
survivorship
self-directed care
e-health
ASICA
Self-directed care
Melanoma
Survivorship
Primary care
Randomised controlled trial
Cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13063-019-3453-xLicence: CC BY

Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma
© The Author(s). 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Final published version, 1.29 MBLicence: CC BY

Fingerprint

Dive into the research topics of 'Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma'. Together they form a unique fingerprint.

Promoting innovation in remote and rural healthcare
Philip Wilson (Participant), Alasdair Mort (Participant), Ehud Reiter (Participant), Christopher Mellish (Participant), Judith Francoise Maria Masthoff (Participant) & Peter Murchie (Participant)
Impact: Policy, Health and Wellbeing, Societal

Cite this

Murchie, P., Masthoff, J., Walter, F. M., Rahman, K., Allan, J. L., Burrows, N., Proby, C., Lee, A. J., Johnston, M., Durrani, A., Depasquale, I., Brant, B., Neilson, A., Meredith, F., Treweek, S. P., Hall, S. J., & McDonald, A. M. (2019). Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma. Trials, 20, Article 318. https://doi.org/10.1186/s13063-019-3453-x

Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma. / Murchie, Peter (Corresponding Author); Masthoff, Judith; Walter, Fiona M. et al.
In: Trials, Vol. 20, 318, 03.06.2019.

Research output: Contribution to journal › Article › peer-review

Murchie, P, Masthoff, J, Walter, FM, Rahman, K, Allan, JL, Burrows, N, Proby, C, Lee, AJ , Johnston, M, Durrani, A, Depasquale, I, Brant, B, Neilson, A, Meredith, F, Treweek, SP, Hall, SJ & McDonald, AM 2019, 'Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma', Trials, vol. 20, 318. https://doi.org/10.1186/s13063-019-3453-x

@article{82f024900793432da90f836be9c28003,

title = "Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma",

abstract = "BackgroundMelanoma is common; 15,906 people in the UK were diagnosed with melanoma in 2015 and incidence has increased fivefold in 30 years. Melanoma affects old and young people, with poor prognosis once metastatic. UK guidelines recommend people treated for cutaneous melanoma receive extended outpatient, hospital follow up to detect recurrence or new primaries. Such follow up of the growing population of melanoma survivors is burdensome for both individuals and health services. Follow up is important since approximately 20% of patients with early-stage melanoma experience a recurrence and 4–8% develop a new primary; the risk of either is highest in the first 5 years. Achieving Self-directed Integrated Cancer Aftercare (ASICA) is a digital intervention to increase total-skin-self-examination (TSSE) by people treated for melanoma, with usual follow up.MethodsWe aim to recruit 240 adults with a previous first-stage 0-2C primary cutaneous melanoma, from secondary care in North-East Scotland and the East of England. Participants will be randomised to receive the ASICA intervention (a tablet-based digital intervention to prompt and support TSSE) or control group (treatment as usual). Patient-reported and clinical data will be collected at baseline, including the modified Melanoma Worry Scale (MWS), the Hospital Anxiety and Depression Scale (HADs), the EuroQoL 5-dimension 5-level questionnaire (EQ-5D-5 L), and questions about TSSE practice, intentions, self-efficacy and planning. Participants will be followed up by postal questionnaire at 3, 6 and 12 months following randomization, along with a 12-month review of clinical data. The primary timepoint for outcome analyses will be12 months after randomisation.DiscussionIf the ASICA intervention improves the practice of TSSE in those affected by melanoma, this may lead to improved psychological well-being and earlier detection of recurrent and new primary melanoma. This could impact both patients and National Health Service (NHS) resources. This study will determine if a full-scale randomised controlled trial can be undertaken in the UK NHS to provide the high-quality evidence needed to determine the effectiveness of the intervention. ASICA is a pilot study evaluating the effectiveness of the practice of digitally supported TSSE in those affected by melanoma.Trial registrationClinical Trials.gov, NCT03328247. Registered on 1 November 2017.",

keywords = "primary care, melanoma, cancer, randomised controlled trial, survivorship, self-directed care, e-health, ASICA, Self-directed care, Melanoma, Survivorship, Primary care, Randomised controlled trial, Cancer",

author = "Peter Murchie and Judith Masthoff and Walter, {Fiona M.} and Kazi Rahman and Allan, {Julia L.} and Nigel Burrows and Charlotte Proby and Lee, {Amanda J.} and Marie Johnston and Amer Durrani and Ivan Depasquale and Billy Brant and Aileen Neilson and Fiona Meredith and Treweek, {Shaun P.} and Hall, {Susan J.} and McDonald, {Alison M.}",

note = "The authors gratefully acknowledge Joanna Kaniewska, Anne Duncan and Lynda Constable (trial management) for their contributions to the protocol and management of the study. Funding The study is supported by a grant from a Cancer Research UK Population Research Committee project award (C10673/A21685). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Cancer Research UK. The funder (through their peer review and funding board review process) approved the study proposal but had no role in the collection, analysis, or interpretation of data, or writing of the report.",

year = "2019",

month = jun,

day = "3",

doi = "10.1186/s13063-019-3453-x",

language = "English",

volume = "20",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma

T2 - Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma

AU - Murchie, Peter

AU - Masthoff, Judith

AU - Walter, Fiona M.

AU - Rahman, Kazi

AU - Allan, Julia L.

AU - Burrows, Nigel

AU - Proby, Charlotte

AU - Lee, Amanda J.

AU - Johnston, Marie

AU - Durrani, Amer

AU - Depasquale, Ivan

AU - Brant, Billy

AU - Neilson, Aileen

AU - Meredith, Fiona

AU - Treweek, Shaun P.

AU - Hall, Susan J.

AU - McDonald, Alison M.

N1 - The authors gratefully acknowledge Joanna Kaniewska, Anne Duncan and Lynda Constable (trial management) for their contributions to the protocol and management of the study. Funding The study is supported by a grant from a Cancer Research UK Population Research Committee project award (C10673/A21685). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Cancer Research UK. The funder (through their peer review and funding board review process) approved the study proposal but had no role in the collection, analysis, or interpretation of data, or writing of the report.

PY - 2019/6/3

Y1 - 2019/6/3

N2 - BackgroundMelanoma is common; 15,906 people in the UK were diagnosed with melanoma in 2015 and incidence has increased fivefold in 30 years. Melanoma affects old and young people, with poor prognosis once metastatic. UK guidelines recommend people treated for cutaneous melanoma receive extended outpatient, hospital follow up to detect recurrence or new primaries. Such follow up of the growing population of melanoma survivors is burdensome for both individuals and health services. Follow up is important since approximately 20% of patients with early-stage melanoma experience a recurrence and 4–8% develop a new primary; the risk of either is highest in the first 5 years. Achieving Self-directed Integrated Cancer Aftercare (ASICA) is a digital intervention to increase total-skin-self-examination (TSSE) by people treated for melanoma, with usual follow up.MethodsWe aim to recruit 240 adults with a previous first-stage 0-2C primary cutaneous melanoma, from secondary care in North-East Scotland and the East of England. Participants will be randomised to receive the ASICA intervention (a tablet-based digital intervention to prompt and support TSSE) or control group (treatment as usual). Patient-reported and clinical data will be collected at baseline, including the modified Melanoma Worry Scale (MWS), the Hospital Anxiety and Depression Scale (HADs), the EuroQoL 5-dimension 5-level questionnaire (EQ-5D-5 L), and questions about TSSE practice, intentions, self-efficacy and planning. Participants will be followed up by postal questionnaire at 3, 6 and 12 months following randomization, along with a 12-month review of clinical data. The primary timepoint for outcome analyses will be12 months after randomisation.DiscussionIf the ASICA intervention improves the practice of TSSE in those affected by melanoma, this may lead to improved psychological well-being and earlier detection of recurrent and new primary melanoma. This could impact both patients and National Health Service (NHS) resources. This study will determine if a full-scale randomised controlled trial can be undertaken in the UK NHS to provide the high-quality evidence needed to determine the effectiveness of the intervention. ASICA is a pilot study evaluating the effectiveness of the practice of digitally supported TSSE in those affected by melanoma.Trial registrationClinical Trials.gov, NCT03328247. Registered on 1 November 2017.

AB - BackgroundMelanoma is common; 15,906 people in the UK were diagnosed with melanoma in 2015 and incidence has increased fivefold in 30 years. Melanoma affects old and young people, with poor prognosis once metastatic. UK guidelines recommend people treated for cutaneous melanoma receive extended outpatient, hospital follow up to detect recurrence or new primaries. Such follow up of the growing population of melanoma survivors is burdensome for both individuals and health services. Follow up is important since approximately 20% of patients with early-stage melanoma experience a recurrence and 4–8% develop a new primary; the risk of either is highest in the first 5 years. Achieving Self-directed Integrated Cancer Aftercare (ASICA) is a digital intervention to increase total-skin-self-examination (TSSE) by people treated for melanoma, with usual follow up.MethodsWe aim to recruit 240 adults with a previous first-stage 0-2C primary cutaneous melanoma, from secondary care in North-East Scotland and the East of England. Participants will be randomised to receive the ASICA intervention (a tablet-based digital intervention to prompt and support TSSE) or control group (treatment as usual). Patient-reported and clinical data will be collected at baseline, including the modified Melanoma Worry Scale (MWS), the Hospital Anxiety and Depression Scale (HADs), the EuroQoL 5-dimension 5-level questionnaire (EQ-5D-5 L), and questions about TSSE practice, intentions, self-efficacy and planning. Participants will be followed up by postal questionnaire at 3, 6 and 12 months following randomization, along with a 12-month review of clinical data. The primary timepoint for outcome analyses will be12 months after randomisation.DiscussionIf the ASICA intervention improves the practice of TSSE in those affected by melanoma, this may lead to improved psychological well-being and earlier detection of recurrent and new primary melanoma. This could impact both patients and National Health Service (NHS) resources. This study will determine if a full-scale randomised controlled trial can be undertaken in the UK NHS to provide the high-quality evidence needed to determine the effectiveness of the intervention. ASICA is a pilot study evaluating the effectiveness of the practice of digitally supported TSSE in those affected by melanoma.Trial registrationClinical Trials.gov, NCT03328247. Registered on 1 November 2017.

KW - primary care

KW - melanoma

KW - cancer

KW - randomised controlled trial

KW - survivorship

KW - self-directed care

KW - e-health

KW - ASICA

KW - Self-directed care

KW - Melanoma

KW - Survivorship

KW - Primary care

KW - Randomised controlled trial

KW - Cancer

UR - http://www.scopus.com/inward/record.url?scp=85066830276&partnerID=8YFLogxK

UR - https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3453-x

UR - http://www.mendeley.com/research/achieving-selfdirected-integrated-cancer-aftercare-asica-melanoma-protocol-randomised-patientfocused

U2 - 10.1186/s13063-019-3453-x

DO - 10.1186/s13063-019-3453-x

M3 - Article

C2 - 31159849

SN - 1745-6215

VL - 20

JO - Trials

JF - Trials

M1 - 318

ER -

Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: Protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Impacts

Promoting innovation in remote and rural healthcare

Cite this